pharma · Generalized Myasthenia Gravis · Chronic inflammatory demyelinating polyneuropathy (CIDP)
Argenx
argenx
Argenx clinical programs — 22 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 33 Arch Street, Suite 3201, Boston, MA 02110, US
- Founded
- 2008
- Employees
- 2,179
- Programs
- 32
- Drugs
- 16
- Patents
- 0
Argenx projects
22 ClinicalTrials.gov programs sponsored by Argenx.
Argenx has 22 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
ARGX-113
argenx
Primary immune thrombocytopenia
1 trial -
ARGX-113
argenx
Primary Immune Thrombocytopenia
1 trial -
ARGX-113-2007
argenx
Active Idiopathic Inflammatory Myopathy (IIM)
1 trial -
ARGX-113-2008
argenx
Generalized Myasthenia Gravis
1 trial -
ARGX-113-2009
argenx
Bullous Pemphigoid (BP)
1 trial -
ARGX-113-2306
argenx
Primary Sjögren’s Disease
1 trial -
ARGX-113-2308
argenx
Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
1 trial -
ARGX-113-2309
argenx
Thyroid Eye Disease (TED)
1 trial -
ARGX-113-2315
argenx
Ocular Myasthenia Gravis
1 trial -
ARGX-113-2402
argenx
Primary Immune thrombocytopenia (ITP)
1 trial -
ARGX-117-2302
argenx
Multifocal Motor Neuropathy
1 trial -
ARGX-117-2401
argenx
Chronic inflammatory demyelinating polyneuropathy (CIDP)
1 trial -
ARGX-117-2402
argenx
Chronic inflammatory demyelinating polyneuropathy (CIDP)
1 trial -
EFG PH20 SC
argenx
Active Idiopathic Inflammatory Myopathy
1 trial -
Efgartigimod PH20 SC
argenx
Primary Sjogrens Disease
1 trial -
Efgartigimod, Placebo for efgartigimod
argenx
Thyroid Eye Disease (TED)
1 trial -
PBO PH20 SC, ARGX-113
argenx
Bullous Pemphigoid
1 trial -
Placebo for efgartigimod, ARGX-113
argenx
Chronic Idiopathic thrombocytopenic purpura
1 trial -
Vyvgart 1 000 mg solution for injection
argenx
Generalized Myasthenia Gravis
1 trial -
Vyvgart 20 mg/mL concentrate for solution for infusion
argenx
Generalized Myasthenia Gravis (gMG)
1 trial -
Vyvgart 20 mg/mL concentrate for solution for infusion
argenx
Generalized Myasthenia Gravis
1 trial -
efgartigimod PH20 SC
argenx
Bullous Pemphigoid
1 trial
Frequently asked questions
How many clinical projects does Argenx have?
22 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.